Adherence to denosumab for the treatment of osteoporosis in Japanese patients with rheumatoid arthritis: Results from the IORRA cohort study

Click to increase image sizeClick to decrease image size

Acknowledgments

We thank all members of the Institute of Rheumatology, Tokyo Women’s Medical University for the successful management of the IORRA cohort.

Conflict of interest

MN has served on speakers’ bureaus for Daiichi Sankyo, Ono and Shionogi. TF has served on speakers’ bureaus for Asahi Kasei Pharma, Bristol-Myers Squibb, Chugai, Eisai, Ono, Pfizer, Takeda and UCB. EI has received lecture fees from Bristol-Myers Squibb and Pfizer. ET has served on speakers’ bureaus for Abbvie, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Nippon Kayaku, Pfizer, Takeda and UCB. AT has served on speakers’ bureaus for Pfizer. KI has served on speakers’ bureaus for Abbvie, Astellas, Asahi Kasei Pharma, Ayumi, Bristol-Myers Squibb, Eisai, Chugai, Hisamitsu, Janssen, Kaken, Mitsubishi Tanabe, Taisho and Takeda. HY has received a research grant from and has served on speakers’ bureaus for AbbVie, Astellas, Ayumi, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Kaken, Mitsubishi Tanabe, Nippon Shinyaku, Novartis, Ono, Pfizer, Taisho, Takeda, Teijin Pharma, Torii, UCB and YL Biologics. MH has received research grants and/or honoraria from Abbvie, Ayumi, Bristol-Myers Squibb K.K., Chugai, Eisai, Mitsubishi Tanabe, Ono, Taisho, Takeda, Teijin Pharma, and Pfizer, and serves as a consultant for Bristol-Myers Squibb, Chugai, Ono and Pfizer.